Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers
CA 2489214 C · Owner: Etablissement Francais Du Sang-Bretagne · Inventors: Prigent, Claude; Martin, Anne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a monoclonal antibody directed against mammalian aurora-A kinase the method for obtaining same, as well as its uses in cancer diagnosis and prognosis and in pharmaceutical compositions for cancer treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 12, 2003 and granted August 6, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 12, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 12, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.